George R. Blumenshein, MD

Articles by George R. Blumenshein, MD

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

ByRitsuko Komaki, MD,Nora A. Janjan, MD,Jaffer A. Ajani, MD,Patrick M. Lynch, MD,Jackie S. Fairweather, RN,Isaac Raijman, MD,George R. Blumenshein, MD,Linus Ho, MD, PhD,Peter W. T. Pisters, MD,Barry W. Feig, MD,Garrett L. Walsh, MD,Richard Pazdur, MD

December 3rd 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly

Latest Updated Articles

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors
Published: December 3rd 2000 | Updated:

George R. Blumenshein, MD

Articles by George R. Blumenshein, MD

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma